Protara Therapeutics, Inc.

NASDAQ
TARA
Stock
Yield per half year: +4.65%
Dividend yield: 0%
Sector: Healthcare

3.15 $

-0.01 $ -0.3165%
1.62 $
6.67 $

Min/max per year

Share chart Protara Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Protara Therapeutics, Inc.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020.

more details
The company is headquartered in New York, New York.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2014-10-22
ISIN US74365U1079
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Change price per day: -0.3165% (3.16)
Change price per week: -0.6309% (3.17)
Change price per month: -7.35% (3.4)
Change price per 3 month: -7.08% (3.39)
Change price per half year: +4.65% (3.01)
Change price per year: +8.62% (2.9)
Change price per 3 year: -4.83% (3.31)
Change price per 5 year: -87.79% (25.7894)
Change price per year to date: -39.07% (5.17)
All parameters

Grade

Underestimation
Title Value Grade
P/S 0 0
P/BV 0.6506 10
P/E 0 0
Efficiency
Title Value Grade
ROA, % -34.25 0
ROE, % -37.88 0
ROIC, % 0 0
Dividends
Title Value Grade
Dividend yield 0 0
DSI 0 0
Average dividend growth 0 0
Debt
Title Value Grade
Debt/EBITDA -0.0912 10
Debt/Ratio 0.0247 10
Debt/Equity 0.0857 10
Growth impulse
Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 43.73 6
Yield EPS, % -53.23 0
More

Main owners

Institutions Volume Share, %
Opaleye Management Inc. 2 692 594 23.55
Vanguard Group Inc 427 612 3.74
Boxer Capital, LLC 209 227 1.83
Baker Brothers Advisors, LLC 199 671 1.75
Ikarian Capital, LLC 188 664 1.65
Privium Fund Management (UK) Ltd 119 730 1.05
Renaissance Technologies, LLC 113 300 0.99
Geode Capital Management, LLC 78 518 0.69
Bridgeway Capital Management, Inc. 64 000 0.56
Citadel Advisors Llc 38 035 0.33

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Mr. Jesse Shefferman Co-founder, CEO, President & Director 1.02M 1972 (53 years)
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. Co-Founder, Senior VP & Chief Scientific Operations Officer 694.16k 1981 (44 years)
Mr. Patrick Fabbio M.B.A. Chief Financial Officer 696.62k 1968 (57 years)
Ms. Hannah Fry VP, Principal Accounting Officer & Controller N/A 1991 (34 years)
Ms. Mary J. Grendell General Counsel & Corporate Secretary N/A
Ms. Justine O'Malley Senior Vice President of Investor Relations & Corporate Affairs

About company

Address: United States, New York. NY, 345 Park Avenue South - Open in google maps, Open in yandex maps
Website: https://www.protaratx.com